Serum Soluble (Pro) Renin Receptor Level is Increased in Association with Impaired Renal Function in Patients with Autosomal Dominant Polycystic Kidney Disease

Background: The aim of this study was to examine the relationship between the serum soluble prorenin receptor [(P)RR] levels and various clinical parameters of autosomal dominant polycystic kidney disease (ADPKD) patients. Methods: A total of 79 patients with ADPKD were enrolled and their serum soluble (P)RR levels were measured with ELISA kits. Serum creatinine (Cr), urea nitrogen (UN), uric acid (UA), and albumin levels, blood haemoglobin (Hb) concentration, plasma renin activity (PRA), plasma aldosterone concentration (PAC), and urinary protein/Cr ratio were also measured. Results: Univariate analyses showed positive correlations between soluble (P)RR levels and age (P=0.02, r=0.27), serum Cr (P<0.0001, r=0.50), UN (P<0.0001, r=0.45), UA (P=0.04, r=0.23) levels and urinary protein/Cr ratio (P<0.001, r=0.42), negative correlations with estimated glomerular infiltration rate (eGFR) (P<0.0001, r=-0.49) and Hb concentrations (P=0.02, r=-0.26), and no correlation with PRA or PAC levels. Soluble (P)RR levels were positively correlated with total kidney volume (TKV, P<0.01, r=0.35). There was no correlation between soluble (P)RR levels and prescription of renin-angiotensin system inhibitors. Finally, multiple regression analyses showed that serum soluble (P)RR concentration was significantly associated with eGFR after correction TKV. Conclusions: The serum soluble (P)RR levels correlated with their kidney function of the ADPKD patients, suggesting that soluble (P)RR may be involved in kidney injury and promote the progression of renal dysfunction of ADPKD patients.

[1]  A. Ichihara,et al.  Serum Soluble (Pro)Renin Receptor Levels in Maintenance Hemodialysis Patients , 2016, PloS one.

[2]  G. Walz,et al.  Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.

[3]  A. Ichihara,et al.  Roles of the (pro)renin receptor in the kidney. , 2014, World journal of nephrology.

[4]  H. Kobori,et al.  Serum soluble (pro)renin receptor levels in patients with essential hypertension , 2014, Hypertension Research.

[5]  T. Hirose,et al.  Plasma Soluble (Pro)Renin Receptor Is Independent of Plasma Renin, Prorenin, and Aldosterone Concentrations But Is Affected by Ethnicity , 2014, Hypertension.

[6]  P. Fernández-Llama,et al.  Hypertension in autosomal-dominant polycystic kidney disease (ADPKD) , 2013, Clinical kidney journal.

[7]  K. Yuasa,et al.  Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease , 2013, Clinical and Experimental Nephrology.

[8]  P. Gabow,et al.  Hypertension in autosomal dominant polycystic kidney disease , 2013 .

[9]  F. Suzuki,et al.  Soluble (Pro)Renin Receptor and Blood Pressure During Pregnancy: A Prospective Cohort Study , 2012, Hypertension.

[10]  A. Ichihara.  (Pro)renin receptor and autophagy in podocytes , 2012, Autophagy.

[11]  Alexis A Gonzalez,et al.  Soluble Form of the (Pro)Renin Receptor Is Augmented in the Collecting Duct and Urine of Chronic Angiotensin II–Dependent Hypertensive Rats , 2011, Hypertension.

[12]  Y. Ohashi,et al.  Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function , 2010, Clinical and Experimental Nephrology.

[13]  Kazuhiro Takahashi,et al.  Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy , 2010, Peptides.

[14]  C. Cruciat,et al.  Requirement of Prorenin Receptor and Vacuolar H+-ATPase–Mediated Acidification for Wnt Signaling , 2010, Science.

[15]  K. Asayama,et al.  Increased expression of (pro)renin receptor in the remnant kidneys of 5/6 nephrectomized rats , 2010, Regulatory Peptides.

[16]  K. Connelly,et al.  The (Pro)Renin Receptor: Site-Specific and Functional Linkage to the Vacuolar H+-ATPase in the Kidney , 2009, Hypertension.

[17]  V. Torres,et al.  Autosomal dominant polycystic kidney disease: the last 3 years. , 2009, Kidney international.

[18]  H. Kobori,et al.  Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive Patients , 2009, Hypertension.

[19]  G. Nguyen,et al.  Physiology and pharmacology of the (pro)renin receptor. , 2008, Current opinion in pharmacology.

[20]  P. Pandolfi,et al.  A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein , 2006, Circulation research.

[21]  T. Nakayama,et al.  Calcium Channel Blocker versus Angiotensin II Receptor Blocker in Autosomal Dominant Polycystic Kidney Disease , 2005, Nephron Clinical Practice.

[22]  T. Inagami,et al.  The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. , 2004, American journal of physiology. Renal physiology.

[23]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[24]  P K Commean,et al.  Volumetric Measurement of Renal Cysts and Parenchyma Using MRI: Phantoms and Patients with Polycystic Kidney Disease , 2000, Journal of computer assisted tomography.

[25]  D. Wilson,et al.  Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. , 1990, The New England journal of medicine.

[26]  P. Gabow,et al.  Hypertension in autosomal dominant polycystic kidney disease. , 1988, Kidney international.

[27]  D. Wilson,et al.  Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. , 1985, The New England journal of medicine.

[28]  H. Itoh,et al.  Critical roles of (pro)renin receptor-bound prorenin in diabetes and hypertension: sallies into therapeutic approach. , 2008, Journal of the American Society of Hypertension : JASH.

[29]  M. Schalekamp,et al.  Human prorenin: pathophysiology and clinical implications. , 1988, Clinical and experimental hypertension. Part A, Theory and practice.

[30]  Schalekamp Ma,et al.  Human prorenin: pathophysiology and clinical implications. , 1988 .